Fortrea puts sites and investigators at the forefront of clinical trial planning, leveraging their expertise to drive adjustments that will speed trial execution, facilitate study initiation, and increase recruitment efficiency. These adjustments address long-standing demanding situations in clinical trials and will result in a greater on-site testing experience for patients and sponsors. The Site Advisory Committee shall be guilty of providing data and comments on proposed methods and responses related to sites, patients, trial operations, and applicable technology.
“Sites and researchers are critical to the industry at any and all levels of clinical expansion, and historically face demanding situations that are difficult to solve in clinical trials alone. We value their concepts in protocol design and actively engage with them in early conversations with our operating groups and sponsors to temporarily identify the most effective, patient-centered testing plans,” said Mike Clay, vice president of development and growth strategy at Fortrea. “The formation of the Site Advisory Board marks an acceleration of our site-first strategy and includes the representation of incredibly impressive leaders, creating a pool of experts for our industry. The Council will also serve as a cornerstone in our ability to respond to sponsors with data that improves the predictability of their trials, executing in combination to expand effective operational plans. and to provide sponsors with the highest degree of confidence in the timeliness of patient recruitment and overall completion of the trial. “
Advisory board members for Fortrea’s first site include leaders and experts from Circuit Clinical, Elligo Health Research, FutureMeds, Javara, MD Anderson Cancer Center Foundation Spain, ObjectiveHealth, Pratia S. A. and Velocity Clinical Research, representing 440 sites in more than 25 healing spaces and nine countries and offering them to diverse patient communities.
“We strongly believe that this collaborative approach, combining CRO and sites, will enable all stakeholders to better align with the prospects of the clinical trial market,” said Łukasz Bęczkowski, Chief Operating Officer at Pratia. “This definitely allows us to act in combination better. Initiatives like these play a huge role in propelling us all towards positive and accelerated change.
“Fortrea is taking a ‘listen first’ approach by giving sites an equal voice towards the most effective working practices for dynamic patient communities and site stakeholders, leading to the best service to clinical trial sponsors,” said Nick Spittal, chief operations officer at Velocity Clinical Research.
“Fortrea is leading the industry by making partnerships more productive and efficient, from the testing procedure to advertising relationships, all with the purpose of accelerating the time to market for new products,” said Barry Simms, chief operating officer of Elligo Health Research.
“Providing an appropriate patient access solution is critical to determining the success of a clinical trial. Historically, care providers have not been concerned with the initial progression of studies, formulating plans and strategies,” said Colleen Hoke, CEO of ObjectiveHealth. “We strongly support Fortrea’s use of a new state-of-the-art technique to collaborate with healthcare site partner providers, who are critical to achieving good results from successful studies, early in the planning process.
“Working within the vast clinical trial ecosystem is complex and requires highly functional partnerships focused on acceptance and competition,” said Michelle Rule, senior vice president of business optimization at Javara. “Fortrea’s authentic commitment to building forum and executing relationships through the site’s Advisory Board demonstrates a commitment to the progress of all study stakeholders and, most importantly, patients. “
About Fortréa
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical progression and patient responses to the life sciences industry. We collaborate with giant and emerging biopharmaceutical, medical device, and diagnostics corporations to drive healthcare innovation that accelerates the progression of life-changing treatments for patients who need them. Fortrea provides Phase I to IV clinical trial management, clinical pharmacology, differentiated generation test responses, and post-approval services. Fortrea answers are based on 3 decades of delight in more than 20 areas of healing, a pastime for clinical rigor, exceptional wisdom, and a physically powerful network of study sites. Our talented and diverse team of approximately 19,000 people working in more than 90 countries is designed to provide focused, agile responses to consumers around the world. Learn more about how Fortrea is embedding a transformative force, from process to patient, into Fortrea. com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.
Fortrea Contacts: Fortrea Media: Galen Wilson – 703-298-0802, media@fortrea. com Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek. com